An extended set of yeast-based functional assays accurately identifies human disease mutations

Genome Research

Volumn 26, Issue 5, 2016, Pages 670-680

  Sun, Song ^a,b,c,d   Yang, Fan ^a,b,c   Tan, Guihong ^a   Costanzo, Michael ^a   Oughtred, Rose ^e   Hirschman, Jodi ^e   Theesfeld, Chandra L ^e   Bansal, Pritpal ^a,b,c   Sahni, Nidhi ^f,g,i   Yi, Song ^f,g   Yu, Analyn ^a,b,c   Tyagi, Tanya ^a,b,c   Tie, Cathy ^c   Hill, David E ^f,g   Vidal, Marc ^f,g   Andrews, Brenda J ^a   Boone, Charles ^a   Dolinski, Kara ^e   Roth, Frederick P ^a,b,c,f,h  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UPPSALA UNIVERSITY   (Sweden)

^e PRINCETON UNIVERSITY   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h CANADIAN INSTITUTE FOR ADVANCED RESEARCH   (Canada)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRUVATE KINASE; UROPORPHYRINOGEN III SYNTHASE;

ARTICLE; DISEASES; GENE FREQUENCY; GENE MUTATION; GENETIC VARIATION; HUMAN; HUMAN GENOME; MATHEMATICAL MODEL; MISSENSE MUTATION; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; YEAST; GENETIC COMPLEMENTATION; GENETIC DISORDER; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PROCEDURES; SACCHAROMYCES CEREVISIAE;

GENETIC COMPLEMENTATION TEST; GENETIC DISEASES, INBORN; HUMANS; SACCHAROMYCES CEREVISIAE; TRANSCRIPTION, GENETIC;

EID: 84964937674     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.192526.115     Document Type: Article

References (84)

1. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. 2010. A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249.
2. Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, Corn JE, Daley GQ, Doudna JA, Fenner M, et al. 2015. Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science 348: 36-38.
3. Baryshnikova A, Costanzo M, Dixon S, Vizeacoumar FJ, Myers CL, Andrews B, Boone C. 2010. Synthetic genetic array (SGA) analysis in Saccharomyces cerevisiae and Schizosaccharomyces pombe. Methods Enzymol 470: 145-179.
4. Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Ganusova EE, Mudge J, Langley RJ, Zhang L, Lee CC, Schilkey FD, et al. 2011. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 3: 65ra64.
5. Ben-Aroya S, Coombes C, Kwok T, O'Donnell KA, Boeke JD, Hieter P. 2008. Toward a comprehensive temperature-sensitive mutant repository of the essential genes of Saccharomyces cerevisiae. Mol Cell 30: 248-258.
6. Berman H, Henrick K, Nakamura H. 2003. Announcing the worldwide Protein Data Bank. Nat Struct Biol 10: 980.
7. Bienvenu T, des Portes V, Saint Martin A, McDonell N, Billuart P, Carrie A, Vinet MC, Couvert P, Toniolo D, Ropers HH, et al. 1998. Non-specific Xlinked semidominant mental retardation by mutations in a Rab GDPdissociation inhibitor. Hum Mol Genet 7: 1311-1315.
8. Bosley KS, Botchan M, Bredenoord AL, Carroll D, Charo RA, Charpentier E, Cohen R, Corn J, Doudna J, Feng G, et al. 2015. CRISPR germline engineering- the community speaks. Nat Biotechnol 33: 478-486.
9. Brachmann RK, Vidal M, Boeke JD. 1996. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci 93: 4091-4095.
10. Burgess DJ. 2015. Human genetics: somatic mutations linked to future disease risk. Nat Rev Genet 16: 69.
11. Byrne AB, Weirauch MT, Wong V, Koeva M, Dixon SJ, Stuart JM, Roy PJ. 2007. A global analysis of genetic interactions in Caenorhabditis elegans. J Biol 6: 8.
12. Carter H, Douville C, Stenson PD, Cooper DN, Karchin R. 2013. Identifying Mendelian disease genes with the variant effect scoring tool. BMC Genomics 14: S3.
13. Castellana S, Mazza T. 2013. Congruency in the prediction of pathogenic missense mutations: state-of-the-art web-based tools. Brief Bioinform 14: 448-459.
14. Chakravarti A, Clark AG, Mootha VK. 2013. Distilling pathophysiology from complex disease genetics. Cell 155: 21-26.
15. Chan PA, Duraisamy S, Miller PJ, Newell JA, McBride C, Bond JP, Raevaara T, Ollila S, Nystrom M, Grimm AJ, et al. 2007. Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Hum Mutat 28: 683-693.
16. Cherry JM, Hong EL, Amundsen C, Balakrishnan R, Binkley G, Chan ET, Christie KR, Costanzo MC, Dwight SS, Engel SR, et al. 2012. Saccharomyces Genome Database: the genomics resource of budding yeast. Nucleic Acids Res 40: D700-D705.
17. Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, et al. 2011. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci 108: 12372-12377.
18. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. 2012. Predicting the functional effect of amino acid substitutions and indels. PLoS One 7: e46688.
19. Cline MS, Karchin R. 2011. Using bioinformatics to predict the functional impact of SNVs. Bioinformatics 27: 441-448.
20. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, Ding H, Koh JL, Toufighi K, Mostafavi S, et al. 2010. The genetic landscape of a cell. Science 327: 425-431.
21. D'Adamo P, Menegon A, Lo Nigro C, Grasso M, Gulisano M, Tamanini F, Bienvenu T, Gedeon AK, Oostra B, Wu SK, et al. 1998. Mutations in GDI1 are responsible for X-linked non-specific mental retardation. Nat Genet 19: 134-139.
22. Davis EE, Frangakis S, Katsanis N. 2014. Interpreting human genetic variation with in vivo zebrafish assays. Biochim Biophys Acta 1842: 1960-1970.
23. Dimster-Denk D, TrippKW, Marini NJ, Marqusee S, Rine J. 2013. Mono and dual cofactor dependence of human cystathionine β-synthase enzyme variants in vivo and in vitro. G3 3: 1619-1628.
24. Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME. 2013. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol 31: 1267-1270.
25. Exome Aggregation Consortium, Lek M, Karczewski K, Minikel E, Samocha K, Banks E, Fennell T, O'Donnell-Luria A, Ware J, Hill A, et al. 2015. Analysis of protein-coding genetic variation in 60,706 humans. bioRxiv doi: http://dx.doi.org/10.1101/030338.
26. Fowler DM, Stephany JJ, Fields S. 2014. Measuring the activity of protein variants on a large scale using deep mutational scanning. Nat Protoc 9: 2267-2284.
27. Francescatto L, Katsanis N. 2015. Newborn screening and the era of medical genomics. Semin Perinatol 39: 617-622.
28. Frousios K, Iliopoulos CS, Schlitt T, Simpson MA. 2013. Predicting the functional consequences of non-synonymous DNA sequence variants - evaluation of bioinformatics tools and development of a consensus strategy. Genomics 102: 223-228.
29. Fujii H, Yoshida A. 1980. Molecular abnormality of phosphoglycerate kinase- Uppsala associated with chronic nonspherocytic hemolytic anemia. Proc Natl Acad Sci 77: 5461-5465.
30. Fujii H, Krietsch WK, Yoshida A. 1980. A single amino acid substitution (Asp leads to Asn) in a phosphoglycerate kinase variant (PGK Munchen) associated with enzyme deficiency. J Biol Chem 255: 6421-6423.
31. Giaever G, Chu AM, Ni L, Connelly C, Riles L, Veronneau S, Dow S, Lucau- Danila A, Anderson K, Andre B, et al. 2002. Functional profiling of the Saccharomyces cerevisiae genome. Nature 418: 387-391.
32. Gnad F, Baucom A, Mukhyala K, Manning G, Zhang Z. 2013. Assessment of computational methods for predicting the effects of missense mutations in human cancers. BMC Genomics 14: S7.
33. Hart T, Brown KR, Sircoulomb F, Rottapel R, Moffat J. 2014. Measuring error rates in genomic perturbation screens: gold standards for human functional genomics. Mol Syst Biol 10: 733.
34. Heinicke S, Livstone MS, Lu C, Oughtred R, Kang F, Angiuoli SV, White O, Botstein D, Dolinski K. 2007. The Princeton Protein Orthology Database (P-POD): a comparative genomics analysis tool for biologists. PLoS One 2: e766.
35. Herskowitz I. 1987. Functional inactivation of genes by dominant negative mutations. Nature 329: 219-222.
36. Hillenmeyer ME, Fung E, Wildenhain J, Pierce SE, Hoon S, LeeW, Proctor M, St Onge RP, Tyers M, Koller D, et al. 2008. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320: 362-365.
37. Horn T, Sandmann T, Fischer B, Axelsson E, Huber W, Boutros M. 2011. Mapping of signaling networks through synthetic genetic interaction analysis by RNAi. Nat Methods 8: 341-346.
38. Hornbeck PV, Chabra I, Kornhauser JM, Skrzypek E, Zhang B. 2004. PhosphoSite: a bioinformatics resource dedicated to physiological protein phosphorylation. Proteomics 4: 1551-1561.
39. Huang Z, Chen K, Xu T, Zhang J, Li Y, Li W, Agarwal AK, Clark AM, Phillips JD, Pan X. 2011. Sampangine inhibits heme biosynthesis in both yeast and human. Eukaryot Cell 10: 1536-1544.
40. Jeong H, Herskowitz I, Kroetz DL, Rine J. 2007. Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay. PLoS Genet 3: e39.
41. Kachroo AH, Laurent JM, Yellman CM, Meyer AG, Wilke CO, Marcotte EM. 2015. Evolution. Systematic humanization of yeast genes reveals conserved functions and genetic modularity. Science 348: 921-925.
42. Keegan LP, McGurk L, Palavicini JP, Brindle J, Paro S, Li X, Rosenthal JJ, O'Connell MA. 2011. Functional conservation in human and Drosophila of metazoan ADAR2 involved in RNA editing: loss of ADAR1 in insects. Nucleic Acids Res 39: 7249-7262.
43. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. 2014. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 46: 310-315.
44. Kitzman JO, Starita LM, Lo RS, Fields S, Shendure J. 2015. Massively parallel single-amino-acid mutagenesis. Nat Methods 12: 203-206.
45. Kruger WD, Cox DR. 1994. A yeast system for expression of human cystathionine β-synthase: structural and functional conservation of the human and yeast genes. Proc Natl Acad Sci 91: 6614-6618.
46. Kruger WD, Cox DR. 1995. A yeast assay for functional detection of mutations in the human cystathionine β-synthase gene. Hum Mol Genet 4: 1155-1161.
47. Kryukov GV, Pennacchio LA, Sunyaev SR. 2007. Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am J Hum Genet 80: 727-739.
48. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, Maglott DR. 2014. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 42: D980-D985.
49. Laurent JM, Young JH, Kachroo AH, Marcotte EM. 2015. Efforts to make and apply humanized yeast. Brief Funct Genomics doi: 10.1093/bfgp/elv041.
50. Lee MG, Nurse P. 1987. Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 327: 31-35.
51. Lehner B, Crombie C, Tischler J, Fortunato A, Fraser AG. 2006. Systematic mapping of genetic interactions in Caenorhabditis elegans identifies common modifiers of diverse signaling pathways. Nat Genet 38: 896-903.
52. Levitan D, Doyle TG, Brousseau D, Lee MK, Thinakaran G, Slunt HH, Sisodia SS, Greenwald I. 1996. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc Natl Acad Sci 93: 14940-14944.
53. Li Z, Vizeacoumar FJ, Bahr S, Li J, Warringer J, Vizeacoumar FS, Min R, Vandersluis B, Bellay J, Devit M, et al. 2011. Systematic exploration of essential yeast gene function with temperature-sensitive mutants. Nat Biotechnol 29: 361-367.
54. Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzyzanowski PM, Sircoulomb F, Medrano M, Fedyshyn Y, Koh JL, et al. 2012. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov 2: 172-189.
55. Marini NJ, Gin J, Ziegle J, Keho KH, Ginzinger D, Gilbert DA, Rine J. 2008. The prevalence of folate-remedial MTHFR enzyme variants in humans. Proc Natl Acad Sci 105: 8055-8060.
56. Marini NJ, Thomas PD, Rine J. 2010. The use of orthologous sequences to predict the impact of amino acid substitutions on protein function. PLoS Genet 6: e1000968.
57. Marth GT, Yu F, Indap AR, Garimella K, Gravel S, Leong WF, Tyler-Smith C, Bainbridge M, Blackwell T, Zheng-Bradley X, et al. 2011. The functional spectrum of low-frequency coding variation. Genome Biol 12: R84.
58. Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV. 2006. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 34: 1317-1325.
59. Mayfield JA, DaviesMW, Dimster-Denk D, Pleskac N, McCarthy S, Boydston EA, Fink L, Lin XX, Narain AS, Meighan M, et al. 2012. Surrogate genetics and metabolic profiling for characterization of human disease alleles. Genetics 190: 1309-1323.
60. Musso G, Tasan M, Mosimann C, Beaver JE, Plovie E, Carr LA, Chua HN, Dunham J, Zuberi K, Rodriguez H, et al. 2014. Novel cardiovascular gene functions revealed via systematic phenotype prediction in zebrafish. Development 141: 224-235.
61. Nelson MR, Wegmann D, Ehm MG, Kessner D, St Jean P, Verzilli C, Shen J, Tang Z, Bacanu SA, Fraser D, et al. 2012. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science 337: 100-104.
62. Ng PC, Henikoff S. 2001. Predicting deleterious amino acid substitutions. Genome Res 11: 863-874.
63. Osborn MJ, Miller JR. 2007. Rescuing yeast mutants with human genes. Brief Funct Genomic Proteomic 6: 104-111.
64. Ostlund G, Schmitt T, Forslund K, Kostler T, Messina DN, Roopra S, Frings O, Sonnhammer EL. 2010. InParanoid 7: new algorithms and tools for eukaryotic orthology analysis. Nucleic Acids Res 38: D196-D203.
65. Porter CT, Bartlett GJ, Thornton JM. 2004. The Catalytic Site Atlas: a resource of catalytic sites and residues identified in enzymes using structural data. Nucleic Acids Res 32: D129-D133.
66. Pritchard JK. 2001. Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet 69: 124-137.
67. Prowse AB, Timmins NE, Yau TM, Li RK, Weisel RD, Keller G, Zandstra PW. 2014. Transforming the promise of pluripotent stem cell-derived cardiomyocytes to a therapy: challenges and solutions for clinical trials. Can J Cardiol 30: 1335-1349.
68. Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, O'Dushlaine C, Chambert K, Bergen SE, Kahler A, et al. 2014. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 506: 185-190.
69. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, GrodyWW, Hegde M, Lyon E, Spector E, et al. 2015. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17: 405-423.
70. Rine J. 2014. A future of the model organism model. Mol Biol Cell 25: 549-553.
71. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, Ercan-Sencicek AG, DiLullo NM, Parikshak NN, Stein JL, et al. 2012. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485: 237-241.
72. Shady AA, Colby BR, Cunha LF, Astrin KH, Bishop DF, Desnick RJ. 2002. Congenital erythropoietic porphyria: identification and expression of eight novel mutations in the uroporphyrinogen III synthase gene. Br J Haematol 117: 980-987.
73. Sopko R, Huang D, Preston N, Chua G, Papp B, Kafadar K, Snyder M, Oliver SG, Cyert M, Hughes TR, et al. 2006. Mapping pathways and phenotypes by systematic gene overexpression. Mol Cell 21: 319-330.
74. Stranger BE, Stahl EA, Raj T. 2011. Progress and promise of genome-wide association studies for human complex trait genetics. Genetics 187: 367-383.
75. Tardiff DF, Khurana V, Chung CY, Lindquist S. 2014. From yeast to patient neurons and back again: a powerful new discovery platform. Mov Disord 29: 1231-1240.
76. Tennessen JA, Bigham AW,O'Connor TD, FuW, Kenny EE, Gravel S, McGee S, Do R, Liu X, Jun G, et al. 2012. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 337: 64-69.
77. Thusberg J, Olatubosun A, Vihinen M. 2011. Performance of mutation pathogenicity prediction methods on missense variants. Hum Mutat 32: 358-368.
78. Trevisson E, Burlina A, Doimo M, Pertegato V, Casarin A, Cesaro L, Navas P, Basso G, Sartori G, Salviati L. 2009. Functional complementation in yeast allows molecular characterization of missense argininosuccinate lyase mutations. J Biol Chem 284: 28926-28934.
79. van Oijen MG, Slootweg PJ. 2000. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 6: 2138-2145.
80. Wei Q, Wang L, Wang Q, Kruger WD, Dunbrack RL Jr. 2010. Testing computational prediction of missense mutation phenotypes: functional characterization of 204 mutations of human cystathionine β synthase. Proteins 78: 2058-2074.
81. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, Klemm A, Flicek P, Manolio T, Hindorff L, et al. 2014. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 42: D1001-D1006.
82. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, Andre B, Bangham R, Benito R, Boeke JD, Bussey H, et al. 1999. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285: 901-906.
83. Yang X, Boehm JS, Yang X, Salehi-Ashtiani K, Hao T, Shen Y, Lubonja R, Thomas SR, Alkan O, Bhimdi T, et al. 2011. A public genome-scale lentiviral expression library of human ORFs. Nat Methods 8: 659-661.
84. Zhang KJ, Du Y, Zheng ZJ, Gao XC, Huang SP, Li RL, Chen C, Zhang FC. 2008. Relationship between the polymorphisms of GDI1, children NSMR and their intelligence in Qinba region. Yi Chuan 30: 590-594 (in Chinese).